FINWIRES · TerminalLIVE
FINWIRES

Vivid Seats Could Benefit From World Cup Ticket Sales, BofA Says

By

Vivid Seats (SEAT) could benefit from World Cup ticket sales in June, BofA Securities said in a Wednesday note.

"While competition remains a headwind to overall growth, comps get significantly easier for SEAT throughout 2026," the note said.

Positive catalysts for Vivid Seats include growing ticketing industry and wide adoption of the company's loyalty program, among others, the report said.

BofA raised its price target to $8.70 from $7.25 and kept its neutral rating.

Price: $9.64, Change: $+0.96, Percent Change: +11.06%

Related Articles

Australia

Ford Motor Shares Rise After Morgan Stanley Highlights Energy-Storage Deal Potential

Ford Motor (F) shares rose 13% in Wednesday trading after Morgan Stanley said the company had a "fairly high likelihood" of signing energy-storage solutions supply agreements with large commercial customers, including hyperscalers, in the next few months.Ford's licensing agreement with China's Contemporary Amperex Technology, or CATL, is a "key competitive differentiator" that is not fully understood by investors and has been overlooked, Morgan Stanley said Tuesday in a report.The technology licensed from CATL, which is the world's premier energy storage manufacturer, offers Ford the opportunity to allocate capital into a strategic growth area and participate in a fast-growing and relatively high-margin energy-storage market, the report said.Morgan Stanley estimates Ford Energy could generate $500 million to $600 million of run-rate EBIT at 20 GWh of production, with potential upside if capacity expands to meet demand.Ford is set to become one of the US suppliers compliant with the Foreign Entity of Concern rule with proven technology, allowing it to qualify for a 30% investment tax credit, which is an underappreciated competitive advantage, the report said.Morgan Stanley has an equal-weight rating on Ford stock with a price target of $14.Price: $13.59, Change: $+1.60, Percent Change: +13.30%

$F
Australia

BeOne Gets FDA Approval for Beqalzi to Treat Mantle Cell Lymphoma

BeOne Medicines (ONC) said Wednesday the US Food and Drug Administration has granted accelerated approval to Beqalzi for the treatment of adults with relapsed or refractory mantle cell lymphoma, after at least two lines of systemic therapy.The company said continued approval for this indication is contingent upon confirmation of clinical benefit in the confirmatory trial, which is underway.Price: $317.94, Change: $+2.87, Percent Change: +0.91%

$ONC
Australia

Top Midday Gainers

B. Riley adjusted its price target on Vishay Precision Group (VPG) to $109 from $63 while maintaining the stock's buy rating.Shares advanced 18%, with intraday trading volume at over 846,000 from a daily average of about 248,000.Bank of America raised its price target on Coherent (COHR) to $400 from $365, while keeping its neutral rating.Shares advanced 10% as intraday trading volume stood at 4.67 million, compared with a daily average of about 7.58 million.Alibaba (BABA) shares rose 8% amid heavy trading after the company reported a year-over-year jump in fiscal Q4 revenue on Wednesday.More than 30.0 million shares traded intraday compared with a daily average of about 10.5 million.Price: $101.06, Change: $+15.49, Percent Change: +18.10%

$BABA$COHR$VPG